PubMed Health⌕ Search

PubMed · 10729869

Silastic Ring Vertical Gastroplasty Using a Modified TA 90 BNtrade mark.

Abstract

Silastic Ring Vertical Gastroplasty (SRVG) is a well-established method in obesity surgery. In the last 5 years we performed SRVG on 76 patients who suffered from morbid obesity. Not included are those patients who received an SRVG as second or third gastric segmentation operation. In performing the first 27 silastic ring vertical gastroplasties using the TA 90BNtrade mark we repeatedly experienced difficulties in guiding the nasal tube along the lesser curvature through the notch. This problem stimulated us to develop a more simplified procedure of setting the staple-line. In co-operation with AutoSuture Deutschland GmBH, the notched part of the TA 90 BNtrade mark was bent in a 90 degree angle to the left side of the instrument. This way it is much easier to place the nasal tube exactly at the lesser curvature and through the bent notch of the newly developed TA 90 BNK. Thus, we were able to create a sufficient pouch along the lesser curvature. Of 76 patients 27 underwent the SRVG with a TA 90 BNtrade mark and 49 with the TA 90 BNK. The average age of the patients was 39 years, 83% women, 17% men. The overweight ranged from 40 kg to 177 kg, the BMI from 39 to 94. In 12 cases a staple-line rupture occurred, 26% with the TA 90 BNtrade mark and 10% with the TA 90 BNK. In nine patients a reoperative because of stoma stenosis was necessary, 11% with the TA 90 BNtrade mark and 12% with the TA 90 BNK.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A Wolf, B Kortner, HW Kuhlman. 1996. Silastic Ring Vertical Gastroplasty Using a Modified TA 90 BNtrade mark.. https://doi.org/10.1381/096089296765556863

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗